ArticleClinical interventions in aging2026
A Preliminary Predictive Panel for Pre-Frailty Based on Serum Proteomic Biomarkers: A Two-Phase Cross-Sectional Study.
Article in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prefrailty is associated with anomalies in protein metabolism; however, the serum proteomic signatures remain unclear. This study investigated protein profiles across different health statuses and evaluated their potential for the early identification of prefrailty. Methods: Older adults were categorized as robust, prefrail, and frail. Untargeted proteomic screening in a discovery cohort (n = 30) was followed by parallel reaction monitoring (PRM) validation (n = 99). Multidimensional clinical parameters and differentially expressed proteins were integrated within machine learning pipelines to refine the search for characteristic features of prefrailty. Results: 166 proteins were found to be differentially expressed across frailty statuses, with 15 significantly prefrailty-associated proteins subsequently confirmed by PRM validation. These proteins were functionally enriched in pathways related to cell signaling, protein metabolism, immune regulation, and skeletal muscle function maintenance. A Random Forest model, further assembled from gait speed, skeletal muscle mass, E3-independent E2 ubiquitin-conjugating enzyme (UBE2O), Timed Up and Go test time, alpha-actinin-3 (ACTN3), and Mini-Mental State Examination score, exhibited the most robust performance for early frailty identification among multiple algorithms compared. Conclusion: This exploratory study identified candidate serum protein biomarkers associated with prefrailty. Preliminary machine learning models incorporating UBE2O and ACTN3 suggested the feasibility of discriminating prefrailty from robust status, reflecting underlying proteomic heterogeneity among community-dwelling older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.